Detalles de la búsqueda
1.
Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies.
Allergy
; 79(1): 174-183, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37988255
2.
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
Lancet
; 400(10348): 273-282, 2022 07 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-35871814
3.
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
J Eur Acad Dermatol Venereol
; 37(10): 2056-2066, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37335885
4.
Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms: a plain language summary.
Immunotherapy
; 15(13): 975-980, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37254941
5.
Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics.
Clin Transl Immunology
; 11(5): e1390, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35582626
6.
Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study.
Dermatol Ther (Heidelb)
; 12(3): 771-785, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35297025
7.
Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis.
J Allergy Clin Immunol Pract
; 10(12): 3228-3237.e2, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36108923
8.
A Report and Proposals for Future Activity from the Inaugural Artificial Intelligence in Dermatology Symposium Held at the International Societies for Investigative Dermatology 2023 Meeting.
JID Innov
; 4(1): 100236, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38282650
Resultados
1 -
8
de 8
1
Próxima >
>>